Floatz logo

1-(18F)Fluoranyl-3-[[2-[(E)-4-[6-(methylamino)pyridin-3-yl]but-1-en-3-ynyl]-1,3-benzothiazol-6-yl]oxy]propan-2-ol

Vascular Dementia

Chang Gung Memorial HospitalSmall moleculePhase 1/2Dormant
CCC
48/ 100
Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence
33/ 100
Competitive Position
95/ 100

Competitive context

9 Active assets in the Vascular Dementia cohort.

Asset / SponsorPhaseRating
PITTSBURGH COMPOUND B UNLABELLED
National Taiwan University Hospital
Phase 4BB
Risperdal
Janssen-Cilag Pty Ltd
Phase 3BB
6-[4-(1-Cyclohexyl-1H-tetrazol-5-yl)butoxy]-3,4-dihydrocarbostyril
Peking University First Hospital
Phase 4BB
Acetylsalicylic Acid
Peking University First Hospital
Phase 4BB
OXYCODONE HYDROCHLORIDE, HYDROCODONE-
VA Office of Research and Development
Phase 4BB

View all 42 →

Same molecule, other indications

1-(18F)Fluoranyl-3-[[2-[(E)-4-[6-(methylamino)pyridin-3-yl]but-1-en-3-ynyl]-1,3-benzothiazol-6-yl]oxy]propan-2-ol is also rated in:

Alzheimer diseaseDormant
BB
Indicative ·
70 / 100
View asset →
Healthy VolunteersDormant
BB
Indicative ·
64 / 100
View asset →
Alzheimer diseaseDormant
B
Indicative ·
60 / 100
View asset →

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.

Contact →